Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

Published
02 June 2014
From
Medscape
No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers.

Published
29 May 2014
From
NATAP
Calcium and Iron Supplements Lower Dolutegravir Levels When Taken Between Meals

Calcium supplements taken with dolutegravir between meals lowered dolutegravir exposure by one third. Iron supplements with dolutegravir between meals approximately halved dolutegravir exposure. Supplements did not have this effect when taken with dolutegravir with a meal, or when dolutegravir was taken 2 hours before the supplement.

Published
24 May 2014
From
NATAP
Better Late Than Never: Efavirenz Dose Optimization

After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.

Published
03 April 2014
From
Treatment Action Group
Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

The updated guidelines include recommendations for use of newer antiretroviral drugs, including those in new classes, such as CCR5 receptor antagonists and integrase inhibitors. The new guidelines provide additional recommendations regarding use of rifampin with antiretroviral therapy; these recommendations are critical in regions where rifabutin is unavailable.

Published
31 March 2014
From
Morbidity and Mortality Weekly Report
Malnutrition decreases effectiveness of HIV treatment in pregnant African women

In Uganda the prescription of three antiretroviral drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.

Published
19 February 2014
From
Eurekalert Medicine & Health
High incidence of antiretroviral prescribing errors in Nigeria

Antiretroviral prescribing errors are common in Nigeria, according to results of a large prospective study published in PLOS ONE. Errors were detected in the prescriptions of almost all

Published
07 February 2014
By
Michael Carter
Victrelis (boceprevir) label changes update contraindications and drug interactions

On January 17, 2014, FDA approved changes to the Victrelis (boceprevir) package insert to expand the list of contraindicated medications and update the Drug Interaction section.

Published
23 January 2014
From
FDA
Risk of Harmful Drug Interactions Rises With Age in HIV+ US Group

Every 10 years of age independently raised chances that a person in a US HIV cohort would be prescribed an antiretroviral and a nonantiretroviral that should not be given together. One third of cohort members were prescribed medications with moderate or high evidence of a possible drug-drug interaction.

Published
26 November 2013
From
International AIDS Society
Ritonavir the cause of the interaction between telaprevir and ritonavir-boosted atazanavir

Ritonavir is the cause of the detrimental bi-directional interaction between telaprevir and ritonavir-boosted atazanavir, according to Spanish research published in the online edition of Clinical Infectious Diseases. The research involved

Published
25 November 2013
By
Michael Carter

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.